Third Arc Bio Stock
HealthTechLooking to sell Third Arc Bio stock or options?
Third Arc Bio is a biotech company focused on the research and development of multifunctional antibodies. Their platform aims to deliver groundbreaking therapies for solid tumors, inflammation, and immunological disorders by producing antibodies that form immune synapses for precise activation or inhibition of T cells. This enables medical companies to access advanced antibodies for treating immune system-related diseases.
Foresite Capital, T. Rowe Price Group, Freepoint Capital Group, Goldman Sachs Asset Management, Omega Funds, Vida Ventures (Boston), AbbVie Ventures, BVF Partners, Abrdn, Logos Capital, Janus Henderson Investors, Marshall Wace, Cormorant Asset Management, Hillhouse Investment Group.
Our available services for this company
Management Team
Third Arc Bio’s stock FAQs
Third Arc Bio is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Third Arc Bio stock. Depending on Third Arc Bio’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Third Arc Bio stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Third Arc Bio stock in two ways. First, Third Arc Bio employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Third Arc Bio stock. Note that all transactions in Third Arc Bio shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Third Arc Bio stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Third Arc Bio stock. Typically, shares of private companies like Third Arc Bio are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Jul 2024, Third Arc Bio is reported to have closed an equity financing in which the investors valued the company at $305M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Third Arc Bio shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Third Arc Bio is not currently publicly traded, it does not have a ticker symbol.
Third Arc Bio has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Third Arc Bio is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Third Arc Bio shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
